At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HRMY Harmony Biosciences Holdings, Inc.
Market Closed 07-17 16:00:00 EDT
33.77
+0.24
+0.72%
盘后33.77
+0.000.00%
16:30 EDT
High34.22Low33.36Vol705.26K
Open33.43D1 Closing33.53Amplitude2.56%
Mkt Cap1.96BTradable Cap1.73BTotal Shares57.89M
T/O23.81MT/O Rate1.38%Tradable Shares51.15M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Harmony Biosciences Posts Record Q2 WAKIX Revenue
TIPRANKS  ·  07-17 17:31
Harmony Biosciences Posts Record Q2 WAKIX Revenue
Harmony Biosciences Price Target Maintained with a $55.00/share by HC Wainwright & Co.
Dow Jones  ·  07-17 00:31
Harmony Biosciences Price Target Maintained with a $55.00/share by HC Wainwright & Co.
Harmony Biosciences: Strong WAKIX Outperformance and Pipeline Catalysts Support Buy Rating and Unchanged $55 Price Target
TIPRANKS  ·  07-17 00:25
Harmony Biosciences: Strong WAKIX Outperformance and Pipeline Catalysts Support Buy Rating and Unchanged $55 Price Target
Harmony Biosciences Expects Higher Q2 Wakix Revenue; CFO Glenn Reicin Steps Down
MT Newswires Live  ·  07-16 21:06
Harmony Biosciences Expects Higher Q2 Wakix Revenue; CFO Glenn Reicin Steps Down
Harmony Biosciences Reaffirms 2026 Net Revenue Outlook of $1 Billion-$1.04 Billion
Reuters  ·  07-16 20:37
Harmony Biosciences Reaffirms 2026 Net Revenue Outlook of $1 Billion-$1.04 Billion
GUIDANCE: (HRMY) Harmony Biosciences Expects 2026 Net Revenue Range $1.0B - $1.04B, vs. FactSet Est of $1.01B
MT Newswires Live  ·  07-16 20:34
GUIDANCE: (HRMY) Harmony Biosciences Expects 2026 Net Revenue Range $1.0B - $1.04B, vs. FactSet Est of $1.01B
Harmony Biosciences CFO Reicin Steps Down, Names Mollichella Interim Finance Chief
Reuters  ·  07-16 20:33
Harmony Biosciences CFO Reicin Steps Down, Names Mollichella Interim Finance Chief
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-year 2026 Revenue Guidance, and Announces CFO Transition
THOMSON REUTERS  ·  07-16 20:30
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-year 2026 Revenue Guidance, and Announces CFO Transition
Harmony Biosciences - Reiterates Fy2026 Net Product Revenue Guidance of $1 Bln to $1.04 Bln
THOMSON REUTERS  ·  07-16 20:30
Harmony Biosciences - Reiterates Fy2026 Net Product Revenue Guidance of $1 Bln to $1.04 Bln
Harmony Biosciences - Announces Preliminary Q2 2026 Wakix Revenue of Approx $261 Mln, up 30% Year over Year
THOMSON REUTERS  ·  07-16 20:30
Harmony Biosciences - Announces Preliminary Q2 2026 Wakix Revenue of Approx $261 Mln, up 30% Year over Year
Harmony Biosciences - Appoints Stephen Mollichella as Interim Principal Financial Officer
THOMSON REUTERS  ·  07-16 20:30
Harmony Biosciences - Appoints Stephen Mollichella as Interim Principal Financial Officer
Harmony Biosciences - CFO Glenn Reicin Steps Down Effective July 16, 2026
THOMSON REUTERS  ·  07-16 20:30
Harmony Biosciences - CFO Glenn Reicin Steps Down Effective July 16, 2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  07-08
Wall Street Analysts Are Bullish on Top Healthcare Picks
Harmony Biosciences is Maintained at Hold by Deutsche Bank
Dow Jones  ·  07-01
Harmony Biosciences is Maintained at Hold by Deutsche Bank
U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys
Reuters  ·  06-30
U.S. Research Roundup- Comcast, Honeywell Aerospace, Qualys
Analysts Are Bullish on Top Healthcare Stocks: Achieve Life Sciences (ACHV), Harmony Biosciences Holdings (HRMY)
TIPRANKS  ·  06-24
Analysts Are Bullish on Top Healthcare Stocks: Achieve Life Sciences (ACHV), Harmony Biosciences Holdings (HRMY)
Harmony Biosciences spotlights Phase 3 HBS-301 narcolepsy, idiopathic hypersomnia studies at SLEEP 2026
Reuters  ·  06-11
Harmony Biosciences spotlights Phase 3 HBS-301 narcolepsy, idiopathic hypersomnia studies at SLEEP 2026
Harmony Biosciences to present six narcolepsy, idiopathic hypersomnia posters at SLEEP 2026 meeting
Reuters  ·  06-11
Harmony Biosciences to present six narcolepsy, idiopathic hypersomnia posters at SLEEP 2026 meeting
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. -- Barrons.com
Dow Jones  ·  06-04
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. -- Barrons.com
Harmony Biosciences to present at Goldman Sachs Global Healthcare Conference fireside chat
Reuters  ·  05-27
Harmony Biosciences to present at Goldman Sachs Global Healthcare Conference fireside chat

Introduction

Company Name.
Harmony Biosciences Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Issue price:
--